OBJECTIVES:  To develop the economic evaluation of Haemate-p® use in the treatment of Von Willebrand's disease (EVW) as Gold Standard therapy versus use of coagulation factor treatments combined with different amounts of presentation from the perspective of the third-party payer. METHODS: It was developed the economic evaluation of Haemate-p® use against other coagulation factor treatments combined in different presentation amounts (assuming no superiority or inferiority in terms of safety and tolerance), through a cost minimization analysis in a cohort of patients, simulated at different weights in Kilograms (kg) and under the assumption of cohorts in prophylaxis and per event. The economic evaluation took into account the presentation of Haemate-p® of 1200 IU Von Willebrand Factor (vWF) + 500 IU FVIII and it was compared with presentations of Comparator 1: 375 IU vWF + 500 FVIII and Comparator 2: 1000 vWF + 0 FVIII, wherein the amounts of factor do not define the effectiveness of the therapy; analyzing cost differences in patients from 15 kg of weight to 110 kg of weight. RESULTS: The results are presented as the expenditure summation in use of the number of vials necessary to cover the calculated dose for each patient in a single application, in prophylaxis and per event. The use of Gold Standard therapy for VWD represents a saving of 32.81% to 74.67% in a single application of medication, this variation depends on the combined amounts of factor used in alternative therapies. CONCLUSIONS: The results suggest that, in the use of coagulation factors for VWD treatment, it is necessary to recognize the effects of the different doses in the different presentations of each treatment, on the costs assumed in its application. In this sense, and as a final result, Haemate-p® is presented as the thrifty technology in the treatment of this pathology.